

Washington Vaccine Association Assessment Grid

Updated June 28, 2010

The WVA Assessment Grid only lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health plans, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. These other vaccines are available from the Department of Health (DOH) under the Childhood Vaccine Program. For a complete listing of all vaccines available through the state Childhood Vaccine Program, please visit the DOH web site: <http://www.doh.wa.gov/cfh/Immunize/vaccine/vaccine-supply.htm>.

CPT Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per Dose	Notes
90633	Hepatitis A vaccine, pediatric/adolescent dosage (2-dose schedule), for intramuscular use (Code Price is per dose = 0.5 mL)	Havrix	\$ 28.17	
90648	Haemophilus influenzae b vaccine (Hib), PRP-T conjugate (4-dose schedule), for intramuscular use (Code price is per dose = 0.5 mL)	Act HIB Hiberix	\$ 23.13	Per DOH: Providers may be administering both brands as Hiberix is still in some provider's inventories
90649	Human Papilloma Virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use (Code Price is per dose = 0.5 mL)	Gardasil	\$ 127.66	
90669	Pneumococcal conjugate vaccine, 7 valent, for intramuscular use (Code Price is per 0.5 mL dose)	Prevnar (7-valent)	\$ 82.20	CDC will not allow purchase of Prevnar (7-valent) after 3/12/2010. All utilization to go to Prevnar 13 (90670).
90670	Pneumococcal conjugate vaccine, 13 valent, for intramuscular use (Prevnar 13 was FDA approved on 2/24/10)	Prevnar 13	\$ 106.58	
90680	Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use (Code Price is per dose = 2 mL)	RotaTeq	\$ 68.20	
90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenzae Type B, and poliovirus vaccine, inactivated (DTaP - Hib - IPV), for intramuscular use (Code Price is per one dose = 0.5 mL)	Pentacel	\$ 73.82	
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use (Code price is per 0.5 mL dose)	Daptacel	\$ 23.28	
90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use (Code Price is per 0.5 mL)	MMRII	\$ 47.34	
90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use (Code Price is per one dose = 0.5 mL)	ProQuad	\$ 126.32	
90713	Poliovirus vaccine, inactivated, (IPV), for subcutaneous or intramuscular use (Code Price is per 0.5 mL dose)	IPOL	\$ 24.21	
90714	Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to individuals 7 years or older, for intramuscular use (Code Price is per 0.5 mL)	DECAVAC	\$ 19.10	

CPT Code	CPT Code Description	Trade Name(s)	WVA Assessment Amount per Dose	Notes
90715	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use (Code Price is per dose = 0.5 mL)	BOOSTRIX ADACEL	\$ 36.68	
90716	Varicella virus vaccine, live, for subcutaneous use (Code Price is per 0.5 mL)	Varivax	\$ 78.97	
90718	Tetanus and diphtheria toxoids (Td) adsorbed when administered to individuals 7 years or older, for intramuscular use (Code Price is per 0.5 mL)	MassBiologics	\$ 19.10	Assessment is set to same amount as 90714 (Decavac) since there is no published CDC Private Cost.
90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B and poliovirus vaccine, inactivated (DtaP-HepB-IPV), for intramuscular use (Code price is per 0.5 mL)	Pediarix	\$ 69.31	
90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent), for intramuscular use (Code Price is per dose = 0.5 mL)	Menactra	\$ 101.34	
90744	Hepatitis B vaccine, pediatric/adolescent dosage (3-dose schedule), for intramuscular use (Code price is per dose)	ENGERIX B	\$ 20.94	

NOTE: This is the most recent version of the Washington Vaccine Association Assessment Grid, as updated June 28, 2010. It includes amounts deemed reasonable for build up of Association liquidity given (1) the state's inability to fund vaccination purposes after May 1, 2010 and (2) the Washington Vaccine Association's need to repay assessment prepayments within a reasonable period of time. The Washington Vaccine Association reserves the right to revisit and revise the WVA Assessment Grid from time to time, as necessary or appropriate, to fulfill the purposes set forth in Washington law and its governing documents.